Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Circulating ensembles of tumor-associated cells: A redoubtable new systemic hallmark of cancer.

Akolkar D, Patil D, Crook T, Limaye S, Page R, Datta V, Patil R, Sims C, Ranade A, Fulmali P, Fulmali P, Srivastava N, Devhare P, Apurwa S, Patel S, Patil S, Adhav A, Pawar S, Ainwale A, Chougule R, Apastamb M, Srinivasan A, Datar R.

Int J Cancer. 2019 Nov 30. doi: 10.1002/ijc.32815. [Epub ahead of print]

PMID:
31785151
2.

Adaptive, Iterative, Long-Term Personalized Therapy Management in a Case of Stage IV Refractory NSCLC.

Ranade A, Patil D, Bhatt A, Dhasare R, Datta V, Datar R, Akolkar D.

J Pers Med. 2019 Jul 5;9(3). pii: E34. doi: 10.3390/jpm9030034.

3.

The future of lung cancer therapy: Striding beyond conventional EGFR and ALK treatments.

Iyer S, Prajapati R, Ramesh A, Basavalingegowda M, Todur S, Kavishvar S, Vijaykumar R, Naik R, Kulkarni P, Bhatt AD, Maniar V, Maka V, Thungappa SC, Singhal M, Ranade A, Shafi G.

Mol Clin Oncol. 2019 Apr;10(4):469-475. doi: 10.3892/mco.2019.1811. Epub 2019 Feb 20.

4.

Hepatocellular carcinoma in India.

Bhattacharyya GS, Babu KG, Malhotra H, Ranade AA, Murshed S, Datta D.

Chin Clin Oncol. 2013 Dec;2(4):41. doi: 10.3978/j.issn.2304-3865.2013.09.05.

5.

A multicenter phase II randomized study of Cremophor-free polymeric nanoparticle formulation of paclitaxel in women with locally advanced and/or metastatic breast cancer after failure of anthracycline.

Ranade AA, Bapsy PP, Nag S, Raghunadharao D, Raina V, Advani SH, Patil S, Maru A, Gangadharan VP, Goswami C, Sekhon JS, Sambasivaiah K, Parikh P, Bakshi A, Mohapatra R.

Asia Pac J Clin Oncol. 2013 Jun;9(2):176-81. doi: 10.1111/ajco.12035. Epub 2012 Nov 26.

PMID:
23176568
6.

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.

Burstein HJ, Sun Y, Dirix LY, Jiang Z, Paridaens R, Tan AR, Awada A, Ranade A, Jiao S, Schwartz G, Abbas R, Powell C, Turnbull K, Vermette J, Zacharchuk C, Badwe R.

J Clin Oncol. 2010 Mar 10;28(8):1301-7. doi: 10.1200/JCO.2009.25.8707. Epub 2010 Feb 8.

PMID:
20142587
7.

Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.

Heymach JV, Paz-Ares L, De Braud F, Sebastian M, Stewart DJ, Eberhardt WE, Ranade AA, Cohen G, Trigo JM, Sandler AB, Bonomi PD, Herbst RS, Krebs AD, Vasselli J, Johnson BE.

J Clin Oncol. 2008 Nov 20;26(33):5407-15. doi: 10.1200/JCO.2008.17.3138. Epub 2008 Oct 20.

PMID:
18936474
8.

Clinical experience with gefitinib in Indian patients.

Parikh P, Chang AY, Nag S, Digumarti R, Bhattacharyya GS, Doval DC, Babu G, Chacko RT, Advani S, Ranade A, Aggarwal S, Jagannathan R, Hargreaves L, Thatcher N.

J Thorac Oncol. 2008 Apr;3(4):380-5. doi: 10.1097/JTO.0b013e318168f794.

Supplemental Content

Loading ...
Support Center